Acute Lymphoblastic Leukemia Clinical Trial Landscape

Active Phase 3 ALL Programs (2026)

Active Phase 2 Programs: CAR-T and Immunotherapy

Ph+ ALL and TKI Combinations

What Is Acute Lymphoblastic Leukemia?

Acute lymphoblastic leukemia (ALL) is a malignancy of immature B or T lymphocyte precursors (lymphoblasts). ALL is the most common childhood cancer, representing ~25% of pediatric cancers, and is curable in approximately 90% of children with modern chemotherapy. In adults, however, ALL remains challenging: complete remission rates are high (85-90%) but relapse-free survival drops to 40-50% at 5 years for standard-risk adult disease, and worse for high-risk subgroups.

ALL is broadly classified by lineage (B-cell ALL [B-ALL], ~85%; T-cell ALL [T-ALL], ~15%) and by key cytogenetic/molecular features. The major subtypes include: (1) Philadelphia chromosome-positive ALL (Ph+ ALL, BCR-ABL1), occurs in ~25% of adult ALL, requires TKI + chemotherapy or immunotherapy; (2) Ph-like ALL, a genomic subtype with similar gene expression to Ph+ ALL but lacking BCR-ABL1, carrying similarly poor prognosis; (3) KMT2A-rearranged ALL, present in ~5-10% of adult ALL, sensitive to menin inhibitors; (4) T-ALL, distinct biology from B-ALL, with active trials exploring novel agents including venetoclax, nelarabine combinations, and CD7-directed therapies.

The Immunotherapy Revolution in B-ALL

Blinatumomab: From Salvage to Frontline

The trajectory of blinatumomab in ALL mirrors a now-familiar pattern in oncology: approval in relapsed/refractory disease → MRD+ consolidation → frontline combination. The pivotal E1910 trial demonstrated that adding blinatumomab to standard consolidation chemotherapy in adults with newly diagnosed Ph-negative B-ALL improved 3-year OS from 68% to 85%. This result was practice-changing and immediately incorporated into NCCN guidelines. Active trials are now testing whether blinatumomab can be moved even earlier, into induction, and whether it can replace or reduce chemotherapy intensity in subgroups. The key open question is whether blinatumomab's T-cell engagement mechanism can be fully exploited in the frontline setting, where T-cell health is better preserved than in heavily pretreated patients.

CD19 CAR-T in Adult ALL

Two CD19-directed CAR-T therapies are FDA-approved in ALL: tisagenlecleucel (Kymriah, Novartis) for pediatric and young adult (up to age 25) R/R B-ALL; brexucabtagene autoleucel (Tecartus, Kite/Gilead) for adult R/R B-ALL. Both achieve complete remission in approximately 70-80% of patients, with a subset achieving durable long-term remissions. The clinical challenges are cytokine release syndrome (CRS), neurotoxicity (ICANS), manufacturing time (3-4 weeks), and, critically, CD19 antigen loss in approximately 20-40% of relapses post-CAR-T. Obecabtagene autoleucel (obe-cel) represents an engineering advance targeting reduced T-cell exhaustion through a fast-off binder, with Phase 2 data suggesting potentially higher response rates and lower neurotoxicity.

The Post-CAR-T Problem

As CD19 CAR-T becomes standard care for R/R B-ALL, the "post-CAR-T" relapse population is growing. These patients have exhausted the most powerful available therapy and often have CD19-negative disease that is invisible to CD19-directed agents. The leading strategies include: (1) CD22-directed therapy, inotuzumab ozogamicin or CD22 CAR-T cells, exploiting an antigen that remains expressed after CD19 loss; (2) allogeneic transplant in patients who achieve remission; (3) novel combinations targeting non-CD19/CD22 pathways. NCI's NCT07328503 testing CD22 CAR-T after commercial CD19 CAR-T is one of the most clinically important trials currently opening in adult ALL.

T-Cell ALL: A Different Disease

T-cell ALL (T-ALL) lacks CD19 and CD22, making the blinatumomab/inotuzumab/CD19 CAR-T toolkit largely inapplicable. T-ALL has its own genomic landscape: NOTCH1/FBXW7 mutations (present in ~60%, associated with better prognosis), TAL1 rearrangements, LMO2 overexpression, and JAK/STAT pathway alterations. Treatment relies primarily on chemotherapy intensification with nelarabine (a T-cell-selective purine analog). Novel approaches in development include: venetoclax (BCL-2 expression in T-ALL), gamma-secretase inhibitors (targeting NOTCH1 signaling), CD7-directed CAR-T cells, and JAK inhibitors for JAK-mutant T-ALL. T-ALL remains an area of significant unmet need where the immunotherapy revolution has had limited impact to date.

Key Questions Driving ALL Trials in 2026

• Can blinatumomab eliminate chemotherapy in adult ALL? The MDACC experience in Ph+ ALL (blinatumomab + ponatinib, no chemo) is being extended, can similar approaches work in Ph-negative ALL?
• When to use inotuzumab vs. CD19 CAR-T in R/R B-ALL? Both achieve high response rates; sequencing depends on transplant eligibility, VOD risk, manufacturing time, and center experience.
• How to manage post-CD19 CAR-T relapse? CD22-directed approaches are the leading strategy; head-to-head comparisons are limited.
• Can venetoclax add value in ALL? BCL-2 expression varies by ALL subtype; trials are testing venetoclax combinations in both frontline and relapsed settings.
• What is the optimal treatment for Ph-like ALL? Ph-like ALL has diverse genetic alterations (ABL-class fusions, JAK-STAT alterations, etc.): precision medicine approaches matching therapy to molecular subtype are being tested.

Related Disease Pages

• Acute Myeloid Leukemia (AML) Clinical Trials: menin inhibitors, venetoclax, FLT3
• Chronic Lymphocytic Leukemia (CLL) Clinical Trials: BTK inhibitors, sonrotoclax
• Leukemia Clinical Trials Overview: all leukemia subtypes
• DLBCL Clinical Trials: CAR-T, bispecific antibodies
• Non-Hodgkin Lymphoma Overview

Frequently asked questions